MedTrace Logo

Prospective Evaluation of ENDOSWIR Device Versus Pathology for Squamous Cell Carcinoma of Upper Aerodigestive Tract (ENDOSWIR-VADS)

NCT05318872 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2022-04-12

No results posted yet for this study

Summary

A new medical optical device named ENDOSWIR is tested to determine its ability to determine if tissues are cancer or normal tissue on ex-vivo condition for specimen of ENT squamous cell cancers.

Conditions

  • Head and Neck Neoplasms

Interventions

DEVICE

ENDOSWIR

Patients were enrolled for surgery of their cancer and give their consents to the participation to that study. Characteristics of anonymized patient (sex, age, medical history, and tumoral characteristics) will be collected. During surgery, the excisional specimen will be sent in a fresh state for pathological examination (gold standard). The pathologist will determine 10 zones on a cross-section of the specimen which will be analyzed by SWIR, and compared between the two techniques.

Sponsors & Collaborators

  • Institute for Advanced Biosciences (IAB), Grenoble

    collaborator UNKNOWN

  • Commissariat A L'energie Atomique

    collaborator OTHER_GOV

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Christian Righini, MD, PhD · CHU Grenoble Alpes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2022-09-30
Completion
2023-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05318872 on ClinicalTrials.gov